Genmab Discontinues Late Stage Cancer Therapy Acasunlimab
Genmab has halted the development of acasunlimab, a bispecific antibody cancer therapy, to focus on other programs. This decision follows BioNTech's exit from the project and Genmab's recent acquisition of Merus.
Insights:
Genmab A/S , a leading pharmaceutical firm based in Denmark 
DK, announced on December 29 the discontinuation of its late-stage bispecific antibody cancer therapy, acasunlimab. The decision is part of a strategic move to reallocate resources toward other promising late-stage programs following Genmab's assumption of full responsibility for acasunlimab's development in 2024 after BioNTech SE opted out of the project.
DK, announced on December 29 the discontinuation of its late-stage bispecific antibody cancer therapy, acasunlimab. The decision is part of a strategic move to reallocate resources toward other promising late-stage programs following Genmab's assumption of full responsibility for acasunlimab's development in 2024 after BioNTech SE opted out of the project.Acasunlimab was designed to target the 4-1BB receptor on T cells and natural killer cells, aiming to stimulate an anti-tumor response. Although the clinical data for acasunlimab were described as encouraging, Genmab has chosen to prioritize other assets in its pipeline. The therapy was initially in late-stage development for treating solid tumors, including metastatic non-small cell lung cancer.
